Connection

Thomas Keane to Testosterone

This is a "connection" page, showing publications Thomas Keane has written about Testosterone.
Connection Strength

0.936
  1. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology. 2008 Jun; 71(6):1177-80.
    View in: PubMed
    Score: 0.290
  2. Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data. J Urol. 2021 02; 205(2):554-560.
    View in: PubMed
    Score: 0.175
  3. The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data. J Urol. 2020 Apr; 203(4):743-750.
    View in: PubMed
    Score: 0.163
  4. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb; 67(2):334-41.
    View in: PubMed
    Score: 0.113
  5. Androgen deprivation therapy: past, present and future. BJU Int. 2012 Jun; 109 Suppl 6:1-12.
    View in: PubMed
    Score: 0.098
  6. Editorial comment. Urology. 2012 Jul; 80(1):168.
    View in: PubMed
    Score: 0.098
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.